Curated News
By: NewsRamp Editorial Staff
July 14, 2026
Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis
TLDR
- Quantum BioPharma's LUCID-MS, a potential first-in-class MS therapy, could offer a competitive edge by directly targeting myelin loss.
- LUCID-MS targets myelin integrity restoration; Phase 1 safety data supports advancement to Phase 2 trials after FDA IND submission.
- Quantum BioPharma's LUCID-MS aims to improve life for MS patients by addressing neurodegeneration, not just symptoms.
- Quantum BioPharma also has a royalty deal from unbuzzd, with up to $250M in payments before a reduced perpetual royalty.
Impact - Why it Matters
This news matters because multiple sclerosis affects millions worldwide, and current treatments often focus on immune modulation rather than directly repairing myelin damage. Quantum BioPharma's LUCID-MS could represent a paradigm shift in MS therapy by targeting the root cause of neurodegeneration. If successful in Phase 2 trials, it may offer patients a new hope for slowing or reversing disease progression, potentially improving quality of life and reducing disability. The company's strategic partnerships and royalty streams also indicate a robust business model, making this a significant development for investors and the biotech community.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making significant strides in the treatment of multiple sclerosis (MS) with its proprietary therapy candidate, LUCID-MS. This innovative approach targets demyelination and aims to protect or restore myelin integrity, which is crucial in halting neurodegeneration in MS patients. The company recently reported positive results from Phase 1 clinical studies in healthy volunteers, showing a favorable safety profile and good tolerability. These findings have paved the way for a planned Phase 2 clinical trial in people living with multiple sclerosis, following the submission of an Investigational New Drug application to the U.S. Food and Drug Administration in April 2026. Quantum BioPharma believes LUCID-MS could be a first-in-class therapy because it directly addresses myelin loss and neurodegeneration, rather than relying solely on immune modulation, potentially offering a differentiated treatment option for MS patients.
To support the advancement of LUCID-MS, Quantum BioPharma is planning a partnership with Allucent and engaging with neurological specialists to strengthen operational support for the program. The company is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma focuses on the research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation. Additionally, the company spun out its OTC product unbuzzd to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and a royalty agreement that could generate significant revenue, with 7% of sales until $250 million is reached, then 3% in perpetuity.
The recent news was disseminated by MissionIR, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which helps enhance visibility for companies in the investment community. MissionIR provides services such as press release enhancement, social media distribution, and editorial syndication to over 5,000 outlets. This coverage highlights the potential impact of Quantum BioPharma's work on MS treatment and the company's strategic moves in the biotech sector. For more details, the full article is available at https://ibn.fm/AUhNl.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis
